Violet

Other Names

BanafashaBanafshaBanafsha (Kashmiri)BanafshahBanafshehBanapsaBanofshaBlue violaCommon violetDevon violetEnglish violetFlorist's violetFragrant garden violetFragrant violetGarden violetGul-e-BanafshaParma violetSweet blue violetSweet violetVayiletheViola gonzaloi SennenViola hirta subsp. odorata (L.) FioriViola hirta var. odorata (L.) FioriViola martia Gilib.Viola martii subsp. odorata (L.) Schimp. & Spenn.Viola odorataViola odorata f. odorataViola odorata L.Viola odorata subsp. texidoris SennenViola parmensis BaillyViola tenerrima Halácsy & BraunViola thomsonae ChapmanWood violet

Synopsis

Violet (Viola odorata L.): A Comprehensive Reference Article

1. Identity and Botanical Description

1.1 Nomenclature and Taxonomy

Viola odorata L. is a perennial herb and a species of the family Violaceae. The plant is native to Europe, Asia, and North Africa. It is a species of the genus Viola native to Europe and Asia, but has also been introduced to North America and Australasia. It is commonly known as wood violet. The medicinal plant Viola odorata L. (Violaceae) is popularly known as "Banafshah" in Asia and "sweet violet" in Europe. Additional regional names include Sweet Violet, English Violet, Common Violet, or Garden Violet, and Gulbanafsa in Hindi. In Persian and Unani traditions the plant is called Banafsaj or Banafsheh; it is locally known as "Banafsha" in the Kashmir region.

1.2 Morphology and Plant Parts Used

It is a low-growing trailing plant of fewer than 6 inches in height. The plant has a thick and scaly underground stem, with rooting runners. It possesses heart-shaped leaves with scalloped or slightly serrated edges that are dark green, smooth or sometimes downy underneath, and grow in a rosette. Its distinctive purple flowers, accompanied by dark green heart-shaped serrated leaves, thrive naturally in sunny climates found in tropical regions, often seen growing alongside hedges and along river banks.

The root and the parts that grow above the ground are used to make medicine. Ayurvedic tradition typically uses the flowers and rhizomes — the blooms for syrups and aromatic oils, the roots for decoctions.

1.3 Related Species

The Viola genus contains around 550 species, mostly found in the temperate climates of the world. Many species of violet are used similarly to the common blue violet. Both Viola odorata and Viola tricolor (heartsease/wild pansy) are covered as medicinal species in the herbal literature. Sweet violet and heartsease have similar phytochemical profiles and can often be used interchangeably. Viola tricolor and other plants in the Viola genus (such as V. odorata, or sweet violet) have a long history of use in herbalism and folk medicine, particularly Iranian, Greco-Arab, Ayurvedic and Unani traditional health systems.

1.4 Common Preparations and Dosage Forms

Violet preparations in Traditional Persian Medicine (TPM) include violet oil in the form of nasal or topical application for neurologic and skin disorders, as well as pill, decoction, sweet syrup, and confection or semisolid oral preparations for skin, respiratory, gastrointestinal, and urinary ailments. It is used as a single drug or as an ingredient in various formulations including syrup, decoction, infusion, confection, semisolid preparations, oil, and pill. The plant is available in commerce in three forms: the dried aerial parts of the herb; only the dried flowers; and the aerial parts without flowers.

2. Traditional and Historical Use

2.1 Traditional Persian Medicine (TPM)

The current literature has compiled a review of the chemical composition and medicinal properties of this plant in modern phytotherapy and its related multipotential products from Traditional Persian Medicine (TPM). Medicinal applications of V. odorata and respective products were derived from credible pharmaceutical textbooks of TPM dating from the 10th–18th century AD. Management of cough, fever, common cold, headache, insomnia, epilepsy, constipation, palpitation, dyspnea, dysuria, and skin diseases are among the most documented applications of V. odorata in TPM.

In Iranian medicine, violet oil is traditionally used to treat insomnia. The oil is made using almond or sesame oil with V. odorata and is administered via nasal drops. References in traditional Persian texts describe decoctions, juices, or syrups prepared from V. odorata for treatment of hot fever, inflamed livers, or inflammation in other organs.

2.2 Ayurveda

Documented as early as the Charaka Samhita (circa 4th century CE), Viola odorata was prized in classical texts under the Sanskrit name "Banafsa." Ancient physicians recommended it for Kapha-related respiratory issues — stuffy chest, persistent cough — and even fevers with a dry throat.

2.3 Unani Medicine

The plant has long been used for its medicinal properties in a variety of traditional medical systems, such as Persian, Ayurvedic, and Unani medicine. Sweet violet has been widely used as ethnomedicine in rural areas of Pakistan for the treatment of skin infection, insomnia, inflammation, cough, fever, and cardiovascular diseases, with very low reported adverse side effects. Its leaves are used as an antiseptic in ointment form, and its flowers have a noted laxative effect.

2.4 Avicenna and Medieval Scholarship

In medieval Persia, the powder of violet flowers appeared in Avicenna's Canon of Medicine (Kitāb al-Qānūn fī al-Tibb) to ease bronchitis. Avicenna's work is one of the most cited classical sources on violet in both traditional Persian and Unani textbooks.

2.5 European Herbal Tradition

The sweet violet (Viola odorata, Violaceae) is the principal medicinal and culinary species used in Europe. It has escaped cultivation in many locales, because it is popularly planted for its fragrance. Much of the American use of violets stems from the European herbal tradition. The English herbalist Nicholas Culpeper associated sweet violet with the planet Venus and described it as "mild nature and no way hurtful," and stated that "all the violets are cold and moist, and are used to cool any heat or distemperature of the body."

2.6 Traditional Chinese Medicine and Other Systems

The main uses of V. odorata for respiratory problems are mentioned in different schools of traditional medicine including traditional Chinese medicine, Ayurveda, and TPM. Likewise, the effects of violet are cited in various western herbal sources including the British Herbal Pharmacopoeia, European Pharmacopoeia, and the Physician Desk Reference, where it is focused on as an expectorant and antitussive agent for bronchial catarrh.

3. Phytochemistry: Key Constituents and Active Compounds

3.1 Flavonoids and Phenolic Compounds

HPLC analysis has revealed twelve phenolic acids and ten flavonoids in V. odorata flowers, with gentisic acid (391.37 μg/g), apigenin-7-glucoside (417.22 μg/g), catechin (372.56 μg/g), and rutin (262.73 μg/g) being predominant. UPLC/ESI–MS has further identified 8 phenolic acids and derivatives, 3 flavonols, 4 flavones, 14 flavonoid glycosides, and 5 anthocyanins derived from cyanidin, delphinidin, and petunidin. Three flavonoids — 5,7-dihydroxy-3,6-dimethoxyflavone, luteolin 7-O-glucoside, and kaempferol 3-O-rutinoside — have been isolated and structurally characterized.

Phytochemical studies of different parts of Viola odorata have resulted in the isolation of chemical constituents such as coumarins, caffeic acid, methyl salicylate, flavonoids (quercetin, kaempferol), glycosides (rutin), and terpenoids (stigmasterol). Flowers of V. odorata have been reported to contain approximately 4.0% anthocyanins, 1.1% flavonoids, 0.4% glycoside, 18.0% mucilage, and 8.5% ash.

3.2 Cyclotides

The aqueous extract contains a combination of essential oils, methyl esters, salicylic acid, flavonoids, anthocyanins, saponins, pollen, and coumarin. The most significant active substances of Viola odorata are plant peptides (cyclotides), including cycloviolacin. About 30 cyclotides have been identified from the aerial parts and roots of Viola odorata. Cyclotides are a structurally unique class of head-to-tail cyclized peptides containing three disulfide bonds arranged in a knotted topology that confers exceptional resistance to enzymatic degradation.

A cyclotide named Cycloviolacin O2 (CycO2), isolated from sweet violet, has shown significant bactericidal action against various Gram-negative bacteria such as Pseudomonas aeruginosa, Salmonella typhi, Klebsiella pneumoniae, and Escherichia coli.

3.3 Alkaloids, Saponins, and Other Constituents

An alkaloid violine is found in roots, leaves, flowers, and seeds of V. odorata. It is a volatile compound that forms salts with acids. The plant is rich in many phytoconstituents including saponins, salicylates, alkaloids, flavonoids, tannins, phenolics, coumarins, phenolic glycosides, gaultherin, violutoside, and odoratine. The essential oil of V. odorata contains ionine, saponins, cardiac glycoside, methyl salicylate, mucilage, and vitamins A and C.

The main components identified in V. odorata flower oil include 1-phenyl butanone (22.43%), linalool (7.33%), benzyl alcohol (5.65%), α-cadinol (4.91%), globulol (4.32%), and viridiflorol (3.51%), with pulegone, terpinen-4-ol, germacrene A, and p-methyl anisole present in minor quantities.

3.4 Aqueous vs. Ethanol Extract Profiles

HPLC analysis has revealed that the aqueous extract of V. odorata contains a substantial amount of vitexin (18.81 ± 0.047 mg/g extract), while the ethanol extract also possesses rutin (1.31 ± 0.013 mg/g extract) and vitexin (4.65 ± 0.103 mg/g extract). Three flavonoids — rutin, isovitexin, and kaempferol-6-glucoside — have been isolated from the ethanol extract. These findings highlight that extraction solvent significantly influences constituent profiles.

4. Mechanisms of Action

4.1 Anti-inflammatory Mechanisms

The extract and isolated compounds of V. odorata have exhibited dose-dependent cytotoxicity and anti-inflammatory effects across tested cell lines. Molecular dynamics studies have supported the observed inhibitory mechanisms. Transcription factors regulating NOS2 and COX-2 were used to construct a regulatory network, and five major phytochemicals were screened for target prediction. Selected proteins were subjected to molecular docking, revealing strong interactions between kaempferol-3-O-glucoside and rutin with BChE, NF-κB, and STAT3.

4.2 Antihypertensive Mechanisms

When tested on phenylephrine- and K⁺-induced vasoconstriction, V. odorata crude extract (Vo.Cr) caused concentration-dependent relaxation and caused a rightward shift of Ca²⁺ concentration-response curves, as well as suppression of phenylephrine peaks in Ca²⁺-free medium, similar to that caused by verapamil. In the presence of L-NAME, the relaxation curve was partially inhibited, showing involvement of a nitric oxide (NO)-mediated pathway.

4.3 Cyclotide-Mediated Cytotoxicity

Membrane disruption is a mechanism of cyclotide cytotoxicity evident by liposomal and whole tumor cell leakage, while kalata B1 has been reported to act like a channel through the membrane. NMR analysis revealed the hydrophobic binding of cyclotides to surface membranes. These reports collectively indicate that the primary structure of cyclotides and changes in membrane composition influence their bioactivity and membrane affinities.

4.4 Sedative and Anxiolytic Mechanisms

Rutin, a flavonoid found in violet flowers, has been shown to possess sedative and anxiolytic-like effects through GABAergic neurotransmission. The saponins and mucilage content are additionally regarded as contributing to the plant's expectorant effects, as saponins are known to trigger reflex stimulation of bronchial secretions.

4.5 Antioxidant Activity

The methanol extract of V. odorata was found to be richest in terms of total phenols (37.26 mg GAE/g) and flavonoids (56.90 mg RE/g), and was the most effective as an antiradical (DPPH: 24.91 mg TE/g; ABTS: 66.62 mg TE/g), as well as as an enzyme inhibitor toward cholinesterases, tyrosinase, glucosidase, and amylase.

5. Scientific Evidence by Area of Use

5.1 Insomnia and Sleep Quality

A three-arm double-blind randomized trial enrolled a total of 75 patients with chronic insomnia and randomly assigned them to three groups at the Traditional Iranian Medicine Clinic of Mashhad University of Medical Sciences, Iran. The treatment consisted of intranasal dropping of violet oil, almond oil, or placebo (1% solution of carboxymethyl cellulose) in each nostril every night before sleep for 30 days; three drops of the drug or placebo was used nightly before sleep.

A separate single-arm study administered intranasal drops of violet oil — two drops containing 66 mg of VO in each nostril nightly before sleep for one month — in 50 patients with chronic insomnia. All patients completed an Insomnia Severity Index (ISI) questionnaire before and after one month of treatment. Improvements in sleep and ISI scores were significantly greater in patients after a month of receiving VO drops in comparison with before starting treatment (P < 0.05). A few patients reported some mild complications, but no serious adverse event was encountered. VO was described as a safe, well-tolerated, and effective herbal preparation in patients with chronic insomnia.

ISI scores decreased from 16.32 ± 3.755 at baseline to 12.58 ± 3.592 and 6.48 ± 4.306 after 15 and 30 days of treatment, respectively, suggesting that the response to treatment increases over time, unlike benzodiazepines that cause drug resistance after continued consumption. A randomized clinical trial investigating the effects of V. odorata oil nasal drops on sleep quality in the elderly using the Pittsburgh Sleep Quality Index (PSQI) revealed significant improvements in sleep quality, increases in sleep duration, reductions in sleep disorders, and improvement in sleep onset latency.

A systematic review and meta-analysis of the effect of V. odorata extract in the treatment of insomnia searched PubMed, EMBASE, and Cochrane Library databases. Finally, four articles with five clinical trials including 224 patients were included in the analysis. Evidential note: These insomnia trials are largely conducted in Iran, often without registered control arms for placebo comparison in the single-arm designs, and the multi-herb trials make it difficult to isolate the specific contribution of violet. Evidence is preliminary but consistent.

5.2 Respiratory Conditions

The main uses of V. odorata for respiratory problems are mentioned in different schools of traditional medicine such as traditional Chinese medicine, Ayurveda, and TPM. Likewise, the effects of violet are cited in various western herbal sources including the British Herbal Pharmacopoeia, European Pharmacopoeia, and the Physician Desk Reference, where it is focused on as an expectorant and antitussive agent for bronchial catarrh.

A double-blind, randomized controlled trial (PMID 25954025; J Evid Based Complementary Altern Med, 2015) evaluated a Viola odorata flower syrup for the cough of children with asthma. This was a double-blind, randomized controlled trial published in the Journal of Evidence-Based Complementary and Alternative Medicine (2015). The asthmatic cough trial represents one of the few pediatric human studies in this area.

Several medicinal plants including Viola odorata L. are recommended in traditional Persian medicine for alleviating respiratory infection symptoms. Recent studies have shown anti-inflammatory, antioxidant, anti-asthmatic, antitussive, analgesic, and antibacterial activities of sweet violet. These enhance respiratory functions, reduce pulmonary inflammation, and decline mucous membrane edema.

A randomized triple-blinded, placebo-controlled clinical trial specifically investigated the effect of Viola odorata L. oil for fever in children (Tafazoli V et al., Current Drug Discovery Technologies, 2020). Evidential note: Most respiratory trials are small, single-center, and several test violet as part of a polyherbal combination, which limits attribution of effect to violet alone.

5.3 COVID-19 Symptom Management

A randomized parallel-group double-blind controlled trial was conducted at Al-Zahra general hospital, Isfahan, Iran. This was described as the first clinical trial on the effectiveness of Viola odorata on SARS-CoV-2 patients; it showed that Viola odorata L. effectively controls prevalent manifestations of COVID-19 including cough, myalgia, headache, and diarrhea. The authors suggested that violet syrup could be mentioned as a complementary treatment for viral influenza-like infections in which cough, myalgia, headache, and diarrhea are prominent.

No significant difference was found between groups regarding demographic characteristics and vital signs before and after treatment. Although all symptoms improved significantly in both groups, patients who received violet syrup recovered faster, with mean severity scores of cough (P = 0.025), myalgia (P = 0.036), headache (P = 0.037), and diarrhea (P = 0.044) decreasing greater in the violet group compared to the control group. Violet syrup had no reported side effects in COVID patients in this trial. Evidential note: This was a single-center trial using violet as an add-on to standard treatment; it cannot be interpreted as a standalone anti-viral therapy. The trial has not been replicated.

5.4 Migraine Prevention

A randomized, double-blind, placebo-controlled clinical trial evaluated the effectiveness of a combination of Viola odorata flowers, Rosa damascena flowers, and Coriandrum sativum fruits on severity, duration, and frequency of migraine headaches. The trial was performed on 88 patients who had migraine and visited Besat Neurology Clinic at Kerman University of Medical Sciences, Iran, from September 2016 to March 2017. Patients were randomly divided into intervention (n=44) or placebo groups (n=44). The intervention group received 500 mg capsules three times a day alongside propranolol 20 mg twice daily; the control group received placebo capsules and the same dose of propranolol for four weeks.

In terms of duration, frequency, and severity of headaches between the two groups, the behavior of the two protocols changed over time (p<0.001), and at the end of the 4th week, there was a significant difference between the two groups (p<0.001). In a related quality-of-life trial using the SF36 questionnaire, scores after intervention in the drug group were significantly higher than the control group after 4 weeks, showing that the combination improved quality of life of patients with migraine. Evidential note: These trials tested a three-herb combination alongside propranolol; individual effects of violet cannot be isolated.

5.5 Antihypertensive and Antidyslipidemic Activity

A study was undertaken to provide pharmacological basis for the medicinal use of Viola odorata Linn. in hypertension and dyslipidemia using in vivo and in vitro assays. Viola odorata leaves extract (Vo.Cr), which tested positive for alkaloids, saponins, tannins, phenolics, coumarins, and flavonoids, caused a dose-dependent (0.1–1.0 mg/kg) decrease in mean arterial blood pressure in anaesthetized rats. In isolated guinea-pig atria, Vo.Cr equally inhibited force and rate of spontaneous atrial contractions. Evidential note: This evidence is entirely preclinical (animal/in vitro). No human clinical trials have evaluated V. odorata specifically for blood pressure or lipid outcomes.

5.6 Anticancer and Cytotoxic Activity

In a laboratory study, the methanolic extract of V. odorata flowers exhibited dose-dependent cytotoxicity, with IC₅₀ values of 48.11, 42.42, and 38.65 μg/mL against the proliferation of hepatocellular carcinoma (HepG2), human colonic epithelial cells (Caco-2), and human colorectal carcinoma cells (HTC-116), respectively. Furthermore, the isolated flavonoids exhibited notable cytotoxic effects in liver, colon, and colorectal cell lines, with kaempferol 3-O-rutinoside showing the most potent inhibitory effects compared to the other isolated flavonoids.

Cycloviolacin O2 isolates have exhibited cytotoxic effects. Cyclotide A and kalata B1 have been studied in different works to demonstrate chemotherapeutic activity. The synergistic cytotoxic effects of doxorubicin and Viola odorata extract on the human breast cancer cell line T47-D have also been studied. Evidential note: All anticancer evidence is in vitro or in animal models. There are no human clinical trials evaluating V. odorata as a cancer treatment, and the in vitro findings cannot be extrapolated directly to clinical utility.

5.7 Antimicrobial Activity

Cyclotides cyO2, cyO3, cyO13, and cyO19 have been shown to have potent activity against model fungal plant pathogens (Fusarium oxysporum, F. graminearum, F. culmorum, Mycosphaerella fragariae, Botrytis cinerea), and fungi isolated from violets, with minimal inhibitory concentrations (MICs) ranging from 0.8 μM to 25 μM. Iranian V. odorata extracts have shown antimicrobial activity against Gram-negative bacteria. Methanol and ethanol extracts of the leaves were found active against E. coli (MIC 10 mg/mL), Bacillus subtilis (20 mg/mL), and Pseudomonas aeruginosa (40 mg/mL).

A clinical study referenced in the TPM literature described a decoction of V. odorata administered enterally alongside co-amoxiclav and fexofenadine to help manage tonsillitis and peritonsillar abscess. In traditional medicines, the plant has been well-documented in treating a range of human ailments, including coughs, sore throat, hoarseness, and tonsillitis. Evidential note: Clinical antimicrobial evidence is extremely limited and the available tonsillitis data is from a co-intervention context. The in vitro and cyclotide data are primarily relevant to the plant's own defense mechanisms.

5.8 Neurological and CNS Effects

Collectively, bioactive constituents of the plant exhibit antioxidant and anti-inflammatory properties which ultimately fight against oxidative stress and protect against neurodegeneration. An experimental study found that the analgesic effect of aqueous (p<0.01) and methanolic extract (p<0.05) of Viola odorata at a dose of 400 mg/kg in rats, in the peripheral and central models of pain (tail immersion and hot plate) was significant, but the n-hexane and butanolic extract did not show significant analgesic effects. Evidential note: Neurological benefits are supported principally by animal studies and mechanistic in vitro data; human clinical evidence is limited to the insomnia trials described in section 5.1.

5.9 Melanin Inhibition / Skin

Researchers have investigated the anti-melanogenic effect of extract and fractions of the plant in the B16F10 murine melanoma cell line. The impact of different concentrations of extract and fractions of V. odorata was evaluated on cell viability, cellular tyrosinase, melanin content, mushroom tyrosinase, and ROS production. Viola odorata had no significant cytotoxicity on B16F10 cells compared to the control group. Evidential note: Skin pigmentation data are from in vitro work only.

6. Body Systems and Health Areas Associated with Violet

Respiratory system: Violets have a wide range of medicinal uses. They are typically used for the respiratory, lymphatic, and integumentary systems.
Nervous system / Sleep: Management of headache, insomnia, and epilepsy is documented in TPM.
Cardiovascular system: Traditionally, Viola species have been used to treat cardiovascular conditions.
Digestive / Gastrointestinal system: Management of constipation and dysuria is documented in TPM.
Integumentary / Skin: The plant has been used historically for dermatological conditions.
Musculoskeletal system: The diuretic activities of violet offer a component to treatment of rheumatic conditions. Violet contains salicylates and rutin — two anti-inflammatory compounds considered useful in the treatment of inflammatory musculoskeletal conditions due to their analgesic and anti-inflammatory activities.
Urinary system: It is valued as a diuretic.

7. Dosage Forms and Reported Dosages

The recommended dosage of Viola odorata L. cited in the clinical literature is 2–5 g per day of dry flower.

The following dosages have been reported in specific studies and should be understood in the context of those studies only:

Intranasal violet oil for insomnia: Treatment consisted of intranasal drops of violet oil — two drops containing 66 mg of VO in each nostril — nightly before sleeping for one month.
Intranasal combination formula for insomnia (RCT): Three drops of the drug (violet oil, almond oil, or placebo) in each nostril was used every night before sleep for 30 days.
Migraine prevention capsules: The intervention group received 500 mg capsules of a combination of V. odorata flowers, R. damascena flowers, and C. sativum fruits three times a day for four weeks, alongside propranolol 20 mg twice daily.
Animal analgesic studies: The analgesic effect was studied at a dose level of 200 and 400 mg/kg by oral route in rats; at 400 mg/kg the aqueous and methanolic extracts showed significant analgesic effects.
Animal antihypertensive studies: V. odorata leaves extract caused a dose-dependent (0.1–1.0 mg/kg) decrease in mean arterial blood pressure in anaesthetized rats.

8. Safety Considerations and Drug Interactions

8.1 General Tolerability

In the insomnia trials, a few patients reported some complications about violet oil consumption, most of which were mild, and no serious adverse event was encountered. VO was proposed as a safe and well-tolerated herbal preparation. Violet syrup had no reported side effects in COVID patients in the add-on treatment trial.

8.2 Salicylate Sensitivity

Those with a known hypersensitivity to salicylates should avoid using violets. This is relevant because the plant is rich in salicylates, including methyl salicylate and salicylic acid derivatives, which are structurally related to aspirin.

8.3 Pregnancy and Breastfeeding

Violet preparations are recommended to be avoided in pregnancy and breastfeeding. This precaution is consistent with the plant's known salicylate content; however, controlled human safety data in pregnancy are absent from the published literature.

8.4 Gastrointestinal Effects

Nausea and vomiting may occur in some individuals taking violet preparations. The high saponin content of the plant is a probable contributor to gastrointestinal irritation at higher doses.

8.5 Topical Use on Damaged Skin

For open wounds or larger areas of damaged skin, the herbal literature advises consulting with a qualified medical herbalist before use.

8.6 Species Adulteration and Quality

V. odorata can sometimes be at risk of substitution with other Viola species, and some essential oils have been reported to contain synthetic additives including lillial. V. tricolor is sometimes substituted with Viola arvensis (field pansy), which carries a lower flavonoid content.

8.7 Evidence Gap on Interactions

More studies are needed to confirm the medicinal properties documented in TPM. Some medical applications have been supported by recent studies, but rigorous evaluation of drug interactions with pharmaceuticals is absent from the peer-reviewed literature. The plant's methyl salicylate and salicylic acid content raises a theoretical concern for pharmacodynamic interaction with anticoagulants and non-steroidal anti-inflammatory drugs, but no clinical interaction study has been published.

8.8 Conservation Status

Both V. odorata and V. tricolor are classified as Least Concern on the IUCN Red List of Endangered Species. Both natural and introduced distributions in Europe are widespread and stable.

9. Summary of Evidence Strength

The majority of traditional uses of V. odorata are empirical and are not scientifically validated practices that date many centuries back. Through the development of phytochemical studies and pharmacological testing, knowledge has grown, but a gap remains between traditional and scientific evidence.

There are a small number of human clinical trials, along with some in vivo and in vitro studies that focus on whole plant extracts of violet or a number of its compounds. Violet's effects in respiratory health, insomnia, and cancer have been scientifically explored with some preliminary findings.

The strongest clinical signal is for insomnia, where multiple human trials — including randomized and placebo-controlled designs — have shown statistically significant improvements in sleep scores using intranasal violet oil preparations. For respiratory conditions, there is moderate traditional documentation and a small number of clinical trials, but study quality and sample sizes remain limited. For anticancer, antihypertensive, antidiabetic, and neurological indications, the current evidence base is preclinical (in vitro and animal studies), and no conclusions regarding clinical efficacy can be drawn at this time.

References

Health Conditions

Health conditions that Violet may help support.

No conditions available.

Body Systems

Body systems that Violet may help support.

No body systems available.